The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: Consistency across world geographies and study designs

Pharmacopsychiatry

Volumn 43, Issue 3, 2010, Pages 81-85

  Novick, D ^a   Ascher Svanum, H ^a   Zhu, B ^b   Brnabic, A ^c   Stauffer, V ^b   Peng, X ^b   Karagianis, J ^a,d   Perrin, E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ARTICLE; CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS; DRUG EFFICACY; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EUROPEAN SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOME; HUMAN; INTERCONTINENTAL SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOME; INTERMETHOD COMPARISON; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; UNITED STATES SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EPIDEMIOLOGIC RESEARCH DESIGN; GEOGRAPHY; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PERPHENAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 77952071928     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1242816     Document Type: Article

References (26)

1. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998 317 1309-1312
2. Altman DG, Andersen PK. Calculating the number needed to treat for trials where outcome is time to event. BMJ 1999 319 1492-1495
3. nd edition. Am J Psychiatry 2004 161 1-56
4. Ascher-Svanum H, Faries DE, Zhu B et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006 67 453-460
5. Ascher-Svanum H, Zhu B, Faries D et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004 3 11
6. Ascher-Svanum H, Zhu B, Faries D et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006 6 8
7. Buxton M, Hanney S. How can payback from health services research be assessed? J Health Serv Res Policy 1996 1 35-43
8. Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract 2008 62 837-840
9. Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008 8 1079-1091
10. Citrome L, Stroup TS. Schizophrenia, clinical antipsychotic trials of intervention effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians? Int J Clin Pract 2006 60 933-940
11. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995 310 452-454
12. de Haan L, van Amelsvoort T, Dingemans P et al. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders: a prospective five year follow-up. Pharmacopsychiatry 2007 40 264-268
13. Dossenbach M, Erol A, el Mahfoud Kessaci M et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004 65 312-321
14. Dunayevich E, Ascher-Svanum H, Zhao F et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry 2007 68 1163-1171
15. Faries D, Ascher-Svanum H, Zhu B et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005 5 26
16. Guyatt G, Rennie D. Users Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice Chicago, IL: AMA Press 2002 111
17. Haro JM, Edgell ET, Jones PB et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 2003 107 222-232
18. Haro JM, Suarez D, Novick D et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007 17 235-244
19. Karagianis J, Rosenbluth M, Tohen M et al. Reviewing CATIE for clinicians: Balancing benefit and risk using evidenced-based medicine tools. Curr Med Res Opin 2007 23 2551-2557
20. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006 39 161-170
21. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 1209-1223
22. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 2005 3 21
23. Mller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004 37 (Suppl. 2) S141-S147
24. Stauffer V, Karagianis J, Sutton V et al. Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in randomized controlled trials comparing olanzapine to other antipsychotics for treatment of schizophrenia. Clin Schizophr Related Psychoses 2008 2 136-146
25. Suarez D, Haro JM, Novick D et al. Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. Pharmacopsychiatry 2009 42 135-140
26. Volovka J, Citrome L. All antipsychotics are equal, but some are more equal than others. J Clin Psychiatry 2009 70 429-430